The World Health Organization (WHO) have announced a new statement on the public disclosure of clinical trial results which updates and expands a previous statement that noted the "the registration of all interventional trials is a scientific, ethical, and moral responsibility." The new statement includes timelines by which researchers are expected to report clinical trials results.

The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from August 10th until December 4th, 2015. The program offers mentoring by entrepreneurs and Bayer experts, office space for 100 days at Bayer HealthCare Pharmaceuticals headquarters, and funding of 50,000€.

Would you like to contribute to the future of cancer treatment in technology? iManageCancer project is trying to find out how mobile healthcare (mHealth) and serious games might help people with chronic illnesses and in particular cancer. Significant improvements due to cancer research have led to more cancer patients being cured, and very many more enabled to live with their condition.

Rare diseases - those that affect fewer than one in 200,000 people - are often identified early in life. Some 30 percent of children afflicted by these "orphan diseases" do not live to see their fifth birthday. While the U.S. Orphan Drug Act of 1983 was written into law to promote research on the topic, the cost of identifying the source and progression of these diseases remains prohibitive for many families.

German biotech company Metabolomic Discoveries announced the launch of personalized metabolomics tool Kenkodo. Through a smartphone app and sampling kit, users will soon be able to improve their well­being. Kenkodo is available through the crowdfunding platform Indiegogo. This product offers people the possibility to track and understand the influence of factors, such as nutrition, sports and stress on their metabolism.

The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech - the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic.

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults.